$14.18
1.128.58%
Last update: Nov 10, 8:20 AM
Generate Biomedicines Inc
GENBNASDAQ
Generate Biomedicines rose 12.1% from $12.65 to $14.18, ahead of the S&P 500's +9.7%. Its worst day was Aug 26 (−20.8%), and its low came Mar 6 at $11.21.
Feb 27, 2026 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Generate Biomedicines closed at its lowest level of the year, 11.4% below where the year started.
−10.0% · S&P 500 −1.3%
EPS of $-1.07 missed the $-0.48 estimate on $7.2M revenue (est. $6.0M).
Story events cover the past 12 months · Times ET
−11.2% · S&P 500 −0.3%
Generate Biomedicines shares fell 18.7%, while the S&P 500 fell 0.1%.
−18.7% · S&P 500 −0.1%
Generate Biomedicines shares rose 13.9%, while the S&P 500 rose 0.4%.
+13.9% · S&P 500 +0.4%
EPS of $-0.52 missed the $-0.49 estimate on $6.3M revenue (est. $5.5M).
−4.1% · S&P 500 −0.2%
Generate Biomedicines closed at its highest level of the year, 61.1% above where the year started.
+15.0% · S&P 500 +0.3%
Generate Biomedicines shares rose 16.4%, while the S&P 500 rose 0.3%.
+16.4%, the year's best day · S&P 500 +0.3%
Where it ended: a close of $14.18 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 24, 2026 (EPS est. $-0.54, revenue est. $7.8M).
Nothing in the past 12 months.
All GENB dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for GENB and SPY from Benzinga historical bars. Not investment advice.
